Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy

MedicalXpress | Jul 07, 2026

Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and Drug Administration-approved treatment for this disease.